Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Net Income
Sonoma Pharmaceuticals Inc
Net Income Peer Comparison
Competitive Net Income Analysis
Latest Figures & CAGR of Competitors
Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Net Income
-$5.1m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income
$38.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Net Income
-$275m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income
$2.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
See Also
What is Sonoma Pharmaceuticals Inc's Net Income?
Net Income
-5.1m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Net Income amounts to -5.1m USD.
What is Sonoma Pharmaceuticals Inc's Net Income growth rate?
Net Income CAGR 10Y
2%
Over the last year, the Net Income growth was 25%. The average annual Net Income growth rates for Sonoma Pharmaceuticals Inc have been -45% over the past three years , 18% over the past five years , and 2% over the past ten years .